|1.||Poovorawan, Yong: 5 articles (10/2013 - 03/2002)|
|2.||Gaspar, A M C: 4 articles (05/2008 - 08/2003)|
|3.||de Paula, V S: 4 articles (05/2008 - 01/2001)|
|4.||Theamboonlers, Apiradee: 3 articles (10/2013 - 01/2005)|
|5.||Souto, Francisco José Dutra: 3 articles (08/2012 - 03/2002)|
|6.||Gaspar, Ana Maria Coimbra: 3 articles (08/2012 - 03/2002)|
|7.||Smetana, J: 3 articles (09/2011 - 08/2006)|
|8.||Arankalle, V A: 3 articles (08/2009 - 06/2002)|
|9.||Gaspar, Ana M C: 3 articles (02/2009 - 01/2002)|
|10.||Zhang, Yong: 3 articles (09/2007 - 05/2002)|
|1.||Hepatitis A (Hepatitis, Infectious)
01/01/2008 - "To estimate the prevalence of anti-HAV-T in the group of HIV-positive adults and to assess the efficacy of vaccination against viral hepatitis A. "
07/01/1995 - "[The efficacy of the prevaccination detection of anti-HAV in hepatitis A vaccination programs]."
04/01/1985 - "Positive results of anti-HAV were obtained in the early stage after the onset of hepatitis A. "
08/01/2005 - "A prospective trial was performed to detect seroprevalence of maternal hepatitis A antibodies during the first 2 years of life among young infants born to hepatitis A antibody positive mothers in Turkey. "
08/01/2000 - "Wastewater workers in this study had a higher prevalence of anti-HAV than drinking water workers, which suggested that wastewater workers may have been at increased risk of occupationally acquired hepatitis A. "
09/01/2015 - "BackgroundRural populations present an elevated risk of exposure to hepatitis A virus.ObjectiveThe objective of this study was to estimate the prevalence and risk factors associated with hepatitis A virus infection among residents of rural settlement projects of southwest Goiás, Central Brazil.MethodsA total of 466 residents were interviewed and tested for the detection of anti- hepatitis A virus antibodies by ELISA.ResultsThe global prevalence of anti- hepatitis A virus was 82.2%. "
12/01/2004 - "Lifelong immunity is conferred by infection or vaccination, so anti-HAV seroprevalence studies can be used to indicate which populations are susceptible to infection. "
06/01/2002 - "Our study, comparing with previous reports from other parts in Thailand, indicates a steady decline of anti-HAV prevalence among schoolchildren in Chiang Mai area, and discussed a possibility of an outbreak of HAV infection among urban schoolchildren."
01/01/1992 - "Studies of active and passive immunoprophylaxis were carried out in chimpanzees to determine whether a candidate hepatitis A virus (HAV) vaccine could stimulate antibody to HAV (anti-HAV) that was qualitatively similar to anti-HAV stimulated by natural infection. "
01/01/1983 - "Our studies to date have focused most heavily on the development of a live, attenuated HAV vaccine, although we have also made a prototype killed HAV vaccine form infected marmoset liver which induced anti-HAV and solid immunity to infection in marmosets. "
06/01/2012 - "The aim of the present study was to investigate the seroprevalence of Hepatitis A virus antibodies in patients with clinical symptoms of viral hepatitis and molecular characterization of the detected isolates. "
04/01/2007 - "Patients with the main diagnosis other than hepatitis were screened and 71 % of them were found positive for anti-HCV, 57 % for anti-HBc total and 32 % for anti-HAV total. "
07/01/2005 - "Logistic regression analysis demonstrated a positive correlation of positive anti-HAV test with age, non white color of the skin, absence of sewage treatment and domestic water filter, and a past history of hepatitis. "
06/01/2001 - "The total rate of positive for anti-HAV and anti-HEV was 55.2% (112) in 203 patients with acute hepatitis, 22.2% (45) and 33% (67) were positive separately for anti-HAV and anti-HEV in 112 patients. "
10/15/1994 - "86.3% (CI 95% = 83-93) of the positive anti-HAV subjects reported not having had clinical history of hepatitis. "
01/01/2002 - "Anti-HAV antibody testing was performed on blood samples from a hepatitis B and C study conducted among street youth in 1995-96. "
12/01/2011 - "We used multivariable linear regression to assess the sex-specific, adjusted associations of 'childhood' pathogens [0 (n = 1002), 1 (n = 2199), 2 (n = 3442) or 3 (n = 4833) of HSV1, CMV and hepatitis A antibodies] and 'adult' pathogens [0 (n = 5836), 1 (n = 3018) or ≥ 2 (n = 720) of HSV2, HHV8 and hepatitis B or C) with waist-hip ratio (WHR) and body mass index (BMI) standard deviations (SDs) using NHANES III (1988-94). "
08/01/2011 - "Ten years postvaccination, all subjects were anti-HAV seropositive (≥15 mIU/mL), 81.7% had anti-HBs antibody concentrations ≥10 mIU/mL. All subjects with anti-HBs concentrations <10 mIU/mL, mounted a vigorous anamnestic response to an HBV vaccine challenge dose indicating the presence of immunologic memory against hepatitis B."
03/01/2008 - "Reflex testing of anti-HCV reactive sera for anti-HAV and hepatitis B surface antibody can facilitate appropriate follow-up and timely immunization. "
06/01/2007 - "A past history of injecting drug use was significantly associated with markers for hepatitis B and C; age predicted presence of anti-HAV. "
|5.||Hypertension (High Blood Pressure)
|1.||Immunoglobulin M (IgM)
|3.||Immunoglobulin G (IgG)
|4.||Hepatitis B Vaccines (Hepatitis B Vaccine)
|5.||Hepatitis B Surface Antigens (HBsAg)
|8.||Antigen-Antibody Complex (Immune Complex)
|9.||RNA (Ribonucleic Acid)
|10.||Hepatitis A Vaccines (Hepatitis A Vaccine)
|1.||Transplantation (Transplant Recipients)
|2.||Renal Dialysis (Hemodialysis)
|4.||Day Care (Partial Hospitalization)